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Abstract
The diverse characteristics and large number of entities make metabolite separation challenging in 
metabolomics. To date, there is not a singular instrument capable of analyzing all types of 
metabolites. In order to achieve a better separation for higher peak capacity and accurate 
metabolite identification and quantification, we integrated GC×GC-MS and parallel 2DLC-MS for 
analysis of polar metabolites. To test the performance of the developed system, 13 rats were fed 
different diets to form two animal groups. Polar metabolites extracted from rat livers were 
analyzed by GC×GC-MS, parallel 2DLC-MS (−) and parallel 2DLC-MS (+), respectively. By 
integrating all data together, 58 metabolites were detected with significant change in their 
abundance levels between groups (p ≤ 0.05). Of the 58 metabolites, three metabolites were 
detected in two platforms and two in all three platforms. Manual examination showed that 
discrepancy of metabolite regulation measured by different platforms was mainly caused by the 
poor shape of chromatographic peaks resulted from low instrument response. Pathway analysis 
demonstrated that integrating the results from multiple platforms increased the confidence of 
metabolic pathway assignment.
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1. Introduction
Metabolites are the intermediates and products of all biological processes that take place in a 
biological system. Metabolites can be polar or non-polar, as well as organic or inorganic 
compounds1,2. The diverse chemical characteristics and huge number of entities make 
metabolite separation challenging in metabolomics. Separation methods such as liquid 
chromatography (LC) and gas chromatography (GC) are usually coupled with mass 
spectrometry (MS) to increase the metabolite coverage3. Due to the limited peak capacity of 
a single column, one dimensional separation method using LC or GC can only resolve a 
limited number of metabolites in a biological sample4. In order to obtain better separation 
and higher peak capacity, multi-dimensional separation methods have been developed and 
applied in metabolomics even though the multi-dimensional separation usually needs long 
separation time and reduces the sample throughput5–7.
Comprehensive two-dimensional gas chromatography mass spectrometry (GC×GC-MS) 
uses two capillary GC columns with different stationary phases for separation of 
metabolites8–12. The two columns are usually connected via a thermal modulator. The 
second column is typically much shorter than the first (i.e., 1−2 m as opposed to 30−60 m 
for the first column) and is generally operated at a higher temperature. In the case of 
metabolites that co-elute from the first column, the second column may allow for further 
separation due to the different stationary phases as well as the different column 
temperatures. Thus, GC×GC-MS provides superior chromatographic peak capacity, 
selectivity, and lower detection limit for analysis of metabolites.
Two-dimensional liquid chromatography (2DLC) is usually configured in either a heart-
cutting mode or a comprehensive mode13, 14. The heart-cutting analysis involves the 
collection of a few peaks of interest from the elution of the first dimension column, and then 
subjecting only those peaks onto the second dimension column for further separation. This 
configuration can increase signal-to-noise ratio and improve sensitivity for targeted 
metabolites15. In the comprehensive configuration, eluate from the first dimension column is 
collected into multiple fractions and each fraction is subjected to the second dimension 
column for further separation. The comprehensive 2DLC offers an increased resolution16. 
Most of the 2DLC systems are operated in online mode, where the second dimension 
separation is carried out simultaneously with the first dimension separation17. While the 
online mode of 2DLC has many advantages such as improved reliability and sample 
throughput, shortened analysis time and minimum sample loss, it requires the second 
dimension analysis to be completed during the time needed to collect and transfer a fraction 
from the first dimension column except that the 2DLC was configured in a stop-flow 
mode18. Another limitation of the online 2DLC technique is that the mobile phases used in 
the two columns must be compatible in both miscibility and solvent strength. In addition, 
some metabolites may partition between the fractions collected from the first dimension 
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column, resulting in large variation in metabolite quantification and even metabolite 
identification.
Klavins, et al. developed a parallel 2DLC system to perform orthogonal hydrophilic 
interaction chromatography (HILIC) and reverse phase chromatography (RPC) in one 
analytical run, where a sample was first delivered to two sample loops during sample 
loading19. The two sample aliquots were then simultaneously injected onto a dual column 
setup, and parallel separations were performed on the two columns. The eluates from the 
two columns were then merged and subjected to a mass spectrometer for further analysis. 
This strategy is simple yet effective for coupling HILIC and RPC for the purpose of 
decreasing analysis time and increasing throughput. Furthermore, the parallel 2DLC-MS 
configuration allows the use of two long columns and gradient time to increase separation 
power. However, parallel 2DLC-MS has the potential of peak overlapping which incurs 
resolution problem. On the other hand, unlike the comprehensive 2DLC-MD, parallel 
2DLC-MS does not suffer from the peak partition and solvent miscibility and solvent 
strength issues.
While the effectiveness of both GC×GC-MS and 2DLC-MS for metabolomics has been 
separately demonstrated in multiple studies9, 20–23, analysis of biological samples on the two 
platforms has not yet been explored. In the current study, we aimed to integrate the GC×GC-
MS and the parallel 2DLC-MS for wider metabolite coverage, high confidence of metabolite 
identification and quantification, as well as high confidence of metabolic pathway 
assignment. The performance of developed system was tested by analyzing polar 
metabolites extracted from rat livers, where each metabolite extract was analyzed by 
GC×GC-MS and parallel 2DLC-MS, respectively. After metabolite identification and 
quantification, the performance of GC×GC-MS and parallel 2DLC-MS was assessed based 
on the number of identified metabolites, the accuracy of metabolite quantification, and the 
extent of their pathway coverage.
2. Experimental
2.1. Animal treatment
Thirteen male weanling Sprague–Dawley rats (35–45 g) from the Harlan Laboratories 
(Indianapolis, IN) were fed (ad lib) a purified AIN-76 diet with a defined copper content in 
form of cupric carbonate. The animals were housed in stainless steel cages in a temperature 
and humidity controlled room with a 12:12 h light–dark cycle. The 13 rats formed two 
groups, Group 1 (G1, n=6) and Group 2 (G2, n=7). The rats in G1 received adequate dose of 
copper (6.0 ppm) with free access to deionized water. The rats in G2 received supplemental 
dose of copper (20 ppm) with free access to deionized water containing 30% fructose (w/v). 
Fructose enriched drinking water was changed twice each week. All animals were fed for 4 
weeks. At the end of the feeding period, each rat was killed under anesthesia with 
pentobarbital (50 mg/kg I.P. injection) after overnight fasting. Portions of rat liver were fixed 
with 10% formalin for subsequent sectioning, while others were snap-frozen with liquid 
nitrogen. All animal procedures were performed in accordance with the Guidelines for Care 
and Use of Laboratory Animals of the University of Louisville and approved by the 
American Association of Accreditation of Laboratory Animal Care.
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2.2. Metabolite sample preparation
All samples were processed in random order to avoid systemic bias. After placing about 100 
mg of liver tissue in a 1.5-mL Eppendorf tube, water was added at a ratio of 100 mg 
liver/mL water. After that, glass beads were added to the tube and the sample was 
homogenized using a Retsch MM 200 model mixer mill (Fisher Scientific, Hampton, NH, 
USA). To extract polar metabolites for GC×GC-MS analysis, 800 μL methanol was added to 
200 μL homogenized liver. The mixture was vortex-mixed for 2 min and then placed on ice 
for 10 min. After another 2 min of vortex mixing, the sample was centrifuged at 15,000 rpm 
for 20 min at 4 °C. Seven hundred micro-liters of supernatant was transferred into a glass 
vial and dried in a SpeedVac evaporator to remove methanol, followed by lyophilization to 
remove water. The dried metabolite extract was then dissolved with 30 μL of 20 mg/mL 
methoxyamine hydrochloride pyridine solution followed by vigorous vortex mixing for 1 
min. Methoxymation was carried out by sonicating the sample for 20 min and incubating it 
at 60 °C for 1 h. Derivatization was conducted by adding 30 μL of N-tert-butyldimethylsilyl-
N-methyltrifluoroacetamide with 1% tert-butyldimethylchlorosilane to the glass vial. After 1 
h incubation at 60 °C, the mixture was transferred to a GC vial for analysis. A pooled 
sample was prepared by mixing 30 μL of derivatized metabolite extract from each sample.
To extract polar metabolites for parallel 2DLC-MS analysis, 400 μL methanol was added to 
100 μL homogenized liver. The mixtures was vortex-mixed and centrifuged using the same 
extraction protocol used for GC×GC-MS analysis. Three hundred micro-liters of supernatant 
was transferred into a glass vial. Methanol in the sample was removed using a SpeedVac 
evaporator and water was removed by lyophilization. The dried metabolite extract was 
reconstituted with 100 μL 20% acetonitrile. The reconstitution was immediately preceded 
the parallel 2DLC-MS analysis. A pooled sample was prepared by mixing 50 μL of 
metabolite extract from every sample of the same group.
2.3. GC×GC-MS and its data analysis
A LECO (St. Joseph, MI, USA) Pegasus GC×GC-MS instrument was coupled with an 
Agilent 6890 gas chromatography and a Gerstel MPS2 auto-sampler (GERSTEL Inc., 
Linthicum, MD, USA), featuring a LECO two-stage cryogenic modulator and a secondary 
oven. The primary column was a 60 m × 0.25 mm 1dc × 0.25 μm 1df DB-5 ms capillary 
column (phenyl arylene polymer virtually equivalent to (5%-phenyl)-methylpolysiloxane). 
The secondary GC column was a 1 m × 0.25 mm 2dc × 0.25 μm 2df DB-17 ms column 
((50% phenyl)-methylpolysiloxane) that was placed inside the secondary GC oven following 
the thermal modulator. Both columns were obtained from Agilent Technologies (Agilent 
Technologies J&W, Santa Clara, CA, USA). The helium carrier gas (99.999% purity) flow 
rate was set to 2.0 mL/min at a corrected constant flow with pressure ramps. The inlet 
temperature was set to 280 °C. The primary column temperature was programmed with an 
initial temperature of 60 °C for 0.5 min, then ramped at 5 °C/min to 270 °C, and maintained 
at 270 °C for 15 min. The secondary column temperature program was set to an initial 
temperature of 70 °C for 0.5 min and then ramped at the same temperature gradient used in 
the first column to 280 °C. The thermal modulator was +15 °C compared with the primary 
oven. The other instrument parameters were as: modulation period 2 s, mass range 29–800 
m/z, spectrum acquisition rate 200 mass spectra per second, ion source chamber temperature 
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230 °C, transfer line temperature 280 °C, detector voltage 1420 V, electron energy 70 eV, 
and split ratio 20:1. The acceleration voltage was turned on after a solvent delay of 640 s.
The pooled sample was analyzed by GC×GC-MS eight times. The experiment data of the 
pooled sample were used to monitor the instrument variation. In addition, an aliquot of 
C7−C30 n-alkane series was analyzed for retention index calculation.
To analyze the GC×GC-MS data, LECO’s instrument control software, ChromaTOF 
(version 4.21), was used for peak picking and tentative metabolite identification. The 
threshold of spectral similarity score was set as ≥ 500 with a maximum value of 1000. 
MetPP software was used for retention index matching, peak merging, peak list alignment, 
normalization and statistical significance test24, 25. The p-value threshold was set as p ≤ 
0.001 for retention index matching.
To verify the tentative identification of metabolites detected with significant abundance 
difference between groups, commercially available authentic standards of those compounds 
were analyzed by GC×GC-MS under the identical experimental conditions as those used for 
analyses of biological samples. A tentative metabolite assignment was considered as a 
correct identification only if the experimental information of the authentic metabolite agreed 
with the corresponding information of a chromatographic peak in the biological samples, 
i.e., difference of the first dimension retention time ≤ 10 s, difference of the second 
dimension retention time ≤ 0.06 s, and the mass spectral similarity ≥ 500.
2.4. Parallel 2DLC-MS and its data analysis
All samples were randomly analyzed on a Thermo Q Exactive HF Hybrid Quadrupole-
Orbitrap Mass Spectrometer coupled with a Thermo UltiMate 3000 HPLC system (Thermo 
Fisher Scientific, Inc., Germany). The UltiMate 3000 HPLC system was equipped with a 
hydrophilic interaction chromatography (HILIC) column and a reverse phase 
chromatography (RPC) column that were configured in parallel mode19. The HILIC column 
(SeQuant® ZIC®-cHILIC, 150×2.1 mm i.d., 3 μm) was purchased from EMD Millipore 
(Darmstadt, Germany). The RPC column (ACQUITY UPLC HSS T3, 150×2.1 mm i.d., 1.8 
μm) was purchased from Waters Corp. (Milford, MA, USA). The temperature of those two 
columns was each set to 40 °C. The HILIC column was operated as follows: mobile phase A 
was 10 mM ammonium acetate (pH adjusted to 3.25 with acetate) in water and mobile phase 
B was 100% acetonitrile with 0.1% formic acid. The gradient was: 0.0 min, 95% B; 0.0 to 
5.0 min, 95% B to 35% B; 5.0 to 6.0 min, 35% B; 6.0 to 6.1 min, 35% B to 5% B; 6.1 to 
23.0 min, 5% B; 23.0 to 23.1 min, 5% B to 95% B; 23.1 to 40.0 min, 95% B. The flow rate 
was set to 0.3 mL/min. For the RPC column, the mobile phase A was water with 0.1% 
formic acid and mobile phase B was 100% acetonitrile with 0.1% formic acid. The gradient 
was as follows: 0.0 min, 5% B; 0.0 to 5.0 min, 5% B; 5.0 to 6.1 min, 5% B to 15% B; 6.1 to 
10.0 min, 15% B to 60% B; 10.0 to 12.0 min, 60% B; 12.0 to 14.0 min, 60% B to 100% B; 
14.0 to 27.0 min, 100% B; 27.0 to 27.1 min, 100% B to 5% B; 27.1 to 40.0 min, 5% B. The 
flow rate was 0.4 mL/min.
The metabolite extract of each biological sample or the pooled sample was analyzed by 
2DLC-MS in positive mode (+) and negative mode (−), respectively. The electrospray 
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ionization probe was fixed at level C. The parameters for the probe were set as follows: 
sheath gas 55 arbitrary unit, auxiliary gas 15 arbitrary unit, sweep gas 3 arbitrary unit, spray 
voltage 3.5 kV, capillary temperature 320 °C, S-lens RF level 65.0, and auxiliary gas heater 
temperature 450 °C. The method of mass spectrometer was set as follows: full scan range 
50–750 m/z, resolution 30,000, maximum injection time 50 ms, and automatic gain control 
(AGC) target 1×106 ions for both positive and negative modes.
The pooled sample was also analyzed by 2DLC-MS/MS (−) and 2DLC-MS/MS (+), 
respectively, to acquire the MS/MS spectra of metabolites. The 2DLC-MS/MS method and 
electrospray ionization condition were the same as those used in parallel 2DLC-MS 
analyses. The parameters used for mass spectrometry were as follows: for full-MS scan, 
scan range 50–750 m/z, resolution 30,000, maximum injection time 50 ms, and AGC target 
1×106 ions; for dd-MS2 scan, resolution 15,000, maximum injection time 100 ms, AGC 
target 5×104 ions, loop count 6, isolation window 1.3 m/z, and dynamic exclusion time 1.2 s. 
Each pooled sample was analyzed using 3 collision energies, i.e., 20, 40 and 60 eV, 
respectively.
To analyze the experimental data, all 2DLC-MS (−) and 2DLC-MS (+) data were processed 
using MetSign software for spectrum deconvolution, metabolite assignment, cross-sample 
peak list alignment, normalization, pattern recognition, and statistical significance test26–29. 
Metabolite identification was achieved in MetSign using the 2DLC-MS (−) and 2DLC-MS 
(+) data of biological samples and the 2DLC-MS/MS (−) and 2DLC-MS/MS (+) data of the 
pooled sample. MetSign respectively aligned the 2DLC-MS/MS (−) and 2DLC-MS/MS (+) 
data to the 2DLC-MS (−) and 2DLC-MS (+) data by retention time and parent ion m/z 
values with following thresholds: retention time variation ≤ 0.2 min and parent ion m/z 
variation ≤ 4 ppm. To identify the metabolites in the pooled sample, the parent ion m/z, 
retention time, and MS/MS spectra of a metabolite were matched to the corresponding 
information of 205 metabolite standards recorded in an in-house database, where the 
matching thresholds were set as follows: MS/MS spectral similarity ≥ 0.4, retention time 
difference ≤ 0.15 min, and m/z variation ≤ 4 ppm. The 2DLC-MS/MS (−) and 2DLC-
MS/MS (+) data without a match in the in-house database were further analyzed using 
Compound Discoverer 2.0 software (Thermo Fisher Scientific, Inc., Germany) to match the 
remaining MS/MS spectra to the MS/MS spectra recorded in the Compound Discoverer 
database with a threshold of MS/MS spectral similarity score ≥ 20. For the peaks detected in 
the 2DLC-MS (−) or 2DLC-MS (+) data of biological samples that were not matched to any 
metabolites by MS/MS spectral matching, the m/z values of those parent ions were then 
matched to the compounds recorded in the Human Metabolome Database (HMDB) and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The m/z variation window 
was set ≤ 4 ppm.
3. Results and Discussion
The 2DLC-MS can be operated in either polarity switching mode or in (+) and (−) runs 
separately. In the polarity switching mode, the number of MS/MS scans across 
chromatographic peaks is reduced owing to polarity switching, resulting in some low 
abundance metabolites without MS/MS spectra. In order to maximize the chance of 
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detecting more metabolites, we chose to analyze each sample in the two different ionization 
modes in two separate runs even though this approach reduced the sample throughput.
3.1. Metabolite coverage by GC×GC-MS
Metabolite identification in analysis of GC×GC-MS data was done using the GC×GC-MS 
data of the pooled sample and biological samples by spectral similarity matching followed 
by retention index matching25, 30. Table 1 lists the numbers of detected chromatographic 
peaks and their identification results from the pooled sample and the rat liver samples. Out 
of 13 biological samples, one sample from G1 was detected as an outlier during the peaks 
alignment step due to very smaller number of peaks detected compared to the other samples. 
We believe this was caused by the injection in GC×GC-MS. Therefore, this sample was 
excluded in the subsequent analysis.
While about 3,138 ± 153 chromatographic peaks were detected in the eight injections of the 
pooled sample, 830 ± 91 metabolites were identified. Details of data processing parameters 
are listed in Supplementary Table S1. Using the same set of parameters, 3,314 ± 301 
chromatographic peaks were detected from the biological samples, from which 874 ± 65 
metabolites were identified. A metabolite might be identified from multiple distinct 
chromatographic peaks owing to incomplete derivatization, presence of isomers, or false 
identifications. After removing the redundant metabolite identifications, 434 ± 35 unique 
metabolites were identified from the pooled sample and 461 ± 32 unique metabolites were 
identified from the biological samples.
In GC×GC-MS, metabolites co-eluted from the first dimension GC column might be 
separated by the second dimension GC column (Supplementary Figure S1), which can 
increase the chance of acquiring high quality EI mass spectrum for metabolite identification. 
Despite the excellent instrumental capability, the identification accuracy of current mass 
spectrum matching method is only about 79.6%31–33. Therefore, additional information such 
as retention index must be used to reduce the rate of false identifications34, 35. On average, 
retention index matching removed about 8.9% of false identifications generated by mass 
spectrum matching (Table 1). Overall, only about 13.7% chromatographic peaks detected by 
GC×GC-MS were assigned to metabolites in this study.
3.2. Metabolite coverage by parallel 2DLC-MS
To identify metabolites from the 2DLC-MS data, 2DLC-MS/MS (−) and 2DLC-MS/MS (+) 
data of the pooled sample were first respectively aligned with the 2DLC-MS (−) and 2DLC-
MS (+) data of the biological samples based on the retention time and parent ion m/z of each 
metabolite. The aligned data were then used for metabolite identification. Table 2 
summarizes the identification results of the 2DLC-MS data. We made fresh solvent of 
mobile phase for analysis of three samples by 2DLC-MS, one sample from G1 and two 
samples from G2. In order to avoid the potential problems of solvent change, the experiment 
data of these three samples were not included in Table 2. Details of metabolites identified in 
this study by MS/MS matching are listed in Supplementary Tables S2 and S3.
A total of 15,108 ± 399 and 15,509 ± 681 features were detected from the pooled sample by 
2DLC-MS (−) and 2DLC-MS (+), respectively. Here, a feature in 2DLC-MS data was 
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defined by retention time and isotopic peak m/z value. By parent ion m/z matching, 2,467 
± 144 features in 2DLC-MS (−) and 4,422 ± 153 features in 2DLC-MS (+) of the pooled 
sample were assigned to at least one metabolite in KEGG or HMDB databases. By MS/MS 
spectrum matching, 264 ± 18 metabolites were identified from the 2DLC-MS/MS (−) data 
and 227 ± 7 metabolites were identified from the 2DLC-MS/MS (+) data.
Table 2 also shows that 14,939 ± 269 and 17,617 ± 410 features were detected from the 
biological samples by 2DLC-MS (−) and 2DLC-MS (+), respectively. Among those features, 
3,551 ± 85 and 5,560 ± 180 metabolites were respectively assigned to the 2DLC-MS (−) and 
2DLC-MS (+) data based on parent ion m/z matching. By MS/MS spectrum matching, 262 
± 15 and 200 ± 9 metabolites were identified from the 2DLC-MS/MS (−) and 2DLC-
MS/MS (+), respectively.
By parent ion m/z matching, about 23.8% to 31.6% of metabolites giving rise to the features 
in 2DLC-MS (−) and 2DLC-MS (+) were assigned to at least one metabolite. However, the 
percentage of assignment was dramatically reduced to only 1.1% to 1.8% when the MS/MS 
spectra were used for metabolite identification, even though we maximized the chance of 
acquiring high quality MS/MS spectra for each metabolite by fragmenting each parent ion 
using three collision energies, i.e., 20, 40 and 60 eV, respectively. The extremely low 
percentage of metabolite identification agrees with Silva, et al.’s observation that 98% of the 
instrumental data were not used in metabolomics36. Multiple factors contributed to those 
results. For instance, a fraction of the isotopic peaks detected by MS are not monoisotopic 
peaks and therefore cannot be matched to the metabolites. During the experiment, the top six 
abundant ions were subjected to MS/MS data acquisition in the dd-MS2 mode. A number of 
metabolites with low instrument response were not selected for MS/MS spectra acquisition 
even though they were detected in the full MS mode. Furthermore, a metabolite in the 
sample might not be present in our in-house database and the Compound Discoverer 
database, and therefore could not have an identification result by MS/MS spectrum 
matching.
3.3. Integrating GC×GC-MS and 2DLC-MS data for high metabolite coverage
Figure 1A depicts the identification results of the three analytical platforms GC×GC-MS, 
2DLC-MS (−), and 2DLC-MS (+) in analyzing the polar metabolites extracted from the 
biological samples. A total of 3,965 peaks were assigned to metabolites from the GC×GC-
MS, 2DLC-MS (−), and 2DLC-MS (+) data. A majority of metabolites were assigned by 
parent ion m/z in the 2DLC-MS (−) and 2DLC-MS (+) data, while all metabolites were 
identified from the GC×GC-MS data by mass spectrum matching. Therefore, the number of 
metabolites assigned using the 2DLC-MS (−) and 2DLC-MS (+) data are much larger than 
that using the GC×GC-MS data. Owing to the diverse chemical properties of the GC and LC 
columns, each analytical platform favors detection of different metabolites in the biological 
samples. As expected, the GC×GC-MS and 2DLC-MS have much different metabolite 
coverage. Only 37 metabolites were commonly assigned to the GC×GC-MS and 2DLC-MS 
data. Of those 37 metabolites, 32 metabolites were assigned to the GC×GC-MS and the 
2DLC-MS (−) data, and 28 metabolites were assigned to the GC×GC-MS and 2DLC-MS (+) 
data. There were only 23 metabolites detected by all three analytical platforms.
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Assigning a metabolite to a peak by parent ion m/z only in the analysis of 2DLC-MS data 
generates a very high rate of false assignments. Figure 1B depicts the overlap of metabolite 
identification among GC×GC-MS, 2DLC-MS/MS (−), and 2DLC-MS/MS (+) data by 
MS/MS spectrum matching and other constrains, i.e., retention index filtering in analysis of 
GC×GC-MS data, parent ion m/z matching in analysis of 2DLC-MS/MS (−) and 2DLC-
MS/MS (+) data. A total of 326 metabolites were identified by the three platforms, of which 
205, 120 and 69 metabolites were identified from the GC×GC-MS, 2DLC-MS/MS (−) and 
2DLC-MS/MS (+) data, respectively. Only 22 metabolites were commonly identified in all 
three platforms, which is only 7.0 % of the total metabolites identified by the three 
platforms.
In this study, we employed a parallel 2DLC-MS platform that was configured with a HILIC 
column and a RPC column. The downside of such a configuration is that the metabolite 
coverage was not dramatically increased. Furthermore, one metabolite might be detected 
twice and therefore increased the chance of metabolite overlapping in mass spectrometry. 
However, the parallel 2DLC-MS configuration does not have the problem of metabolite 
partition between two or more fractions that occurs in the comprehensive 2DLC 
configuration. In addition, we can use long columns and long gradient times to improve the 
separation. Overall, each platform, i.e., GC×GC-MS, 2DLC-MS/MS (−), or 2DLC-MS/MS 
(+), has limited metabolite coverage. The number of metabolites commonly detected by all 
those platforms is very small. Therefore, it is necessary to analyze the biological samples on 
different platforms to increase metabolite coverage.
3.4. Integrating GC×GC-MS and parallel 2DLC-MS for accurate metabolite quantification
During the metabolite identification, metabolites assigned by parent ion m/z matching have a 
high ratio of false identifications compared with the identification by MS/MS spectrum 
matching. In order to ensure the high degree of confidence in biomarker discovery, only 
metabolites identified by MS/MS spectrum matching were used for the metabolite 
quantification. A pairwise two-tail t-test with equal variance was used to study the 
abundance change of each metabolite between G1 and G2, during which sample labels were 
permutated up to 1000 times. Supplementary Table S4 shows that 41, 13 and 11 metabolites 
were detected with significant changes in their abundance levels between G1 and G2 in the 
GC×GC-MS, 2DLC-MS (−) and 2DLC-MS (+) data, respectively. Figure 2 shows the 
overlap of those metabolites. It is clear that each platform detected different sets of 
metabolites that had significant changes in their abundance levels. Among those metabolites, 
two were detected by all three platforms and three were detected by two of the three 
platforms. Integrating the results of the three platforms generated a comprehensive set of 
metabolites, i.e., 58 metabolites.
Table 3 lists the details of the abundance information of those five metabolites that were 
detected by more than one platform. The regulation directions of those metabolites detected 
in different platforms agree to each other, i.e., the fold-change of a metabolite detected in 
different platforms are all either larger than 1.0 or less than 1.0. Furthermore, except taurine, 
the fold-changes of those metabolites are almost identical, indicating the robustness and 
accuracy of the three platforms. Figures 3A, 3B, and 3C depict the detection of L-ornithine 
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in different platforms. This metabolite had relatively large instrument response and good 
chromatographic peak shape in all three platforms, and its chromatographic peak did not 
overlap with other compounds. Therefore, the quantification results of this metabolites were 
almost identical among the three platforms, with fold-changes of 0.6, 0.7 and 0.9 in 
GC×GC-MS, 2DLC-MS (−) and 2DLC-MS (+), respectively. However, the fold-change of 
taurine detected by GC×GC-MS had a larger variation compared to those detected by 
2DLC-MS (−) and 2DLC-MS (+). Figures 3E and 3F show that taurine had a good 
instrument response and good peak shape in 2DLC-MS (−) and 2DLC-MS (+), respectively. 
Therefore, the changes of its abundance levels between G1 and G2 detected by 2DLC-MS 
(−) and 2DLC-MS (+) were very similar with fold-change of 1.8 and 1.7, respectively. 
However, the instrument response of taurine in GC×GC-MS was low and its 
chromatographic peak in the second dimension GC was very poor (Figure 3D). Furthermore, 
the chromatographic peak of taurine overlapped with an abundant peak. For those reasons, 
the data analysis software ChromaTOF could not accurately quantify the abundance of 
taurine, and resulted in a large variation in its fold-change compared with the fold-change 
calculated from the 2DLC-MS (−) and 2DLC-MS (+) data.
Overall, the GC×GC-MS, 2DLC-MS (−), and 2DLC-MS (+) platforms implemented in this 
study are robust for metabolite quantification. Manual analysis of the data reveals that the 
variation in metabolite quantification was mainly induced by the poor instrument response 
and the limited accuracy of data analysis software.
3.5. Biomarker discovery and pathway analysis
For metabolic pathway analysis, we first used the metabolites detected by each platform that 
had significant changes in their abundance levels between groups as the input of 
MetaboAnalyst software37, to recognize the pathways that were affected by the treatments of 
rats in G1 and G2. From the 41 significant metabolites found from the GC×GC-MS data, the 
MetaboAnalyst software produced five pathways with p ≤ 0.05 (Table 4). Likewise, 
MetaboAnalyst showed that seven pathways were statistically significant using the 13 
significant metabolites detected from the 2DLC-MS (−) data, and 5 pathways using the 11 
significant metabolites detected from the 2DLC-MS (+) data. We then combined all 58 
significant metabolites detected from the three platforms and used them as the input of 
MetaboAnalyst software. By doing so, eight pathways were considered as significantly 
impacted pathways (Table 4).
Figure 4 shows the overlap of the pathways using different sets of significant metabolites for 
metabolic pathway analysis. Compared with the results of pathway analysis using the data 
acquired by individual platform, the confidence of pathway assignment using the integrated 
data was significantly increased. For instance, 8 metabolites associated with aminoacyl-
tRNA biosynthesis pathway were detected by integrating the data of all three platforms. 
However, 0, 3 and 6 metabolites were detected by 2DLC-MS (−), 2DLC-MS (+) and 
GC×GC-MS, respectively. Using the integrated data acquired from multiple platforms 
clearly increase the confidence of metabolic pathway analysis. The confidence of assigning 
others pathways was also increased, including arginine and proline metabolism; valine, 
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leucine and isoleucine biosynthesis; alanine, aspartate and glutamate metabolism; D-
glutamine and D-glutamate metabolism; and butanoate metabolism.
We also performed another analysis by matching all detected metabolites to the metabolic 
pathway regardless whether those metabolites had significant changes in their abundance 
levels between groups. For example, biosynthesis of unsaturated fatty acid pathway was a 
significantly impacted pathway as suggested by the 58 significant metabolites detected from 
the three platforms. Supplementary Table S5 lists the metabolites in this pathway that were 
detected by different platforms. Docosahexaenoic acid (DHA), linoleic acid (LA), and 
gamma-linolenic acid (GLA), were only detected by GC×GC-MS. Prostaglandin G2, 
leukotriene B4, LXA4/LXB4 were detected by 2DLC-MS (−), and stearidonic acid was only 
detected by 2DLC-MS (+). Detecting more metabolites in a pathway and knowing whether 
their abundance levels were affected by the biomedical treatments clearly can narrow down 
to the specific steps in the pathways that were affected by the treatments.
In summary, one analytical platform is not enough to give high metabolite coverage in a 
metabolic pathway, and the use of only one platform reduces the confidence of metabolic 
pathway assignment. Integrating the data acquired from multiple platforms not only provides 
high metabolite coverage, but also increases the confidence of pathway assignment and the 
confidence of biomarker discovery. The details of the biomarkers and pathways discovered 
in this study will be described in a separate report.
5. Conclusions
Polar metabolites extracted from rat livers were analyzed by GC×GC-MS and parallel 
2DLC-MS, respectively. 903 ± 96 chromatographic peaks were detected by GC×GC-MS, 
and 2,467 ± 144 and 4,422 ± 153 features were respectively detected by 2DLC-MS (−) and 
2DLC-MS (+). Integrating the experimental data acquired from the three platforms clearly 
increased the metabolite coverage. A total of 58 metabolites were detected with significant 
changes in their abundance levels between groups. Three of the 58 metabolites were 
detected in two platforms and two in all three platforms. The agreement of metabolite 
regulation detected by different platforms demonstrated the robustness and accuracy of the 
three platforms used in the current study. Manual examination showed that the discrepancy 
of metabolite regulation measured by different platforms was mainly caused by the poor 
shape of chromatographic peaks. Pathway analysis demonstrated that integrating the results 
from multiple platforms increased the confidence of metabolic pathway assignment. While 
the developed method showed excellent results in terms of metabolites coverage and 
increased confidence of metabolic pathway assignment, however, several factors still need to 
be worked on for better identification and quantification. Metabolite identification still 
remains as a major challenge in untargeted metabolomics. While a huge number of isotopic 
peaks (raw data) were generated from the instrument, most of them remained unidentified. 
Incompleteness of the database contributed to this problem. Future endeavor would be the 
combination of all available MS/MS databases to maximize the metabolite assignment and 
develop robust bioinformatics tools for accurate metabolite identification. Furthermore, a 
comparison of the parallel 2DLC-MS results with the comprehensive 2DLC-MS results 
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would enlighten us the overall capability of the multidimensional analytical technique for 
the untargeted metabolomics.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Overlap of metabolite identification. Metabolites were identified from GC×GC-MS by EI 
mass spectrum matching and retention index matching. (A) The metabolite identification in 
analysis of 2DLC-MS data was done by parent ion m/z matching. (B) The metabolite 
identification in analysis of 2DLC-MS/MS data by MS/MS spectrum matching with or 
without retention time match.
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Figure 2. 
Overlap of metabolites detected with significant changes in their abundance levels between 
groups by three platforms.
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Figure 3. 
Samples of instrument response of a metabolite affecting the quantification accuracy of that 
metabolite. (A) three dimensional chromatographic peak of L-ornithine detected by GC×GC-
MS. (B) extracted ion chromatograms of L-ornithine in a randomly selected biological 
samples detected by 2DLC-MS (−). (C) Extracted ion chromatograms of L-ornithine in a 
randomly selected biological samples detected by 2DLC-MS (+). (D) three dimensional 
chromatographic peak of taurine detected by GC×GC-MS. (E) extracted ion chromatograms 
of taurine in a randomly selected biological samples detected by 2DLC-MS (−). (F) 
Extracted ion chromatograms of taurine in a randomly selected biological samples detected 
by 2DLC-MS (+).
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Figure 4. 
Overlap of the pathways that were affected using different set of significant metabolites for 
metabolic pathway analysis.
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Table 1.
Numbers of detected peaks from pooled sample and biological samples by GC×GC-MS and the results of 
metabolite identification using different matching methods
Sample Analysis ID Chromatographic peaks Metabolite identification
Similarity score threshold ≥ 
500 After RI matching Unique metabolites
Pooled sample
Inj-1 3280 992 911 476
Inj-2 3004 836 778 423
Inj-3 3443 842 778 404
Inj-4 3082 936 862 429
Inj-5 3029 927 864 450
Inj-6 3106 941 637 367
Inj-7 3210 1037 947 447
Inj-8 2952 712 865 477
Average 3138±153 903±96 830±91 434±35
Biological sample
S-1 3389 1017 902 484
S-2 3371 953 842 462
S-3 3304 984 845 469
S-4 3531 1003 918 507
S-5 3873 1080 925 506
S-6 3263 974 881 443
S-7 3062 990 898 458
S-8 3288 1075 954 480
S-9 2559 750 693 399
S-10 3508 961 859 443
S-11 3154 964 846 413
S-12 3463 1048 929 470
Average 3314±301 983±82 874±65 461±32
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Table 2.
Numbers of detected peaks from pooled sample and biological samples by 2DLC-MS and the results of 
metabolite identification using different matching methods
Sample Analysis ID 2DLC-MS (−) 2DLC-MS (+)
Isotopic peaks Public DB MS/MS DB  Isotopic peaks Public DB MS/MS DB
Pooled sample
Inj-1 15586 2706 278  14617 4241 217
Inj-2 14903 2526 276  14834 4215 224
Inj-3 15381 2494 275  14823 4265 217
Inj-4 15196 2564 267  15109 4405 229
Inj-5 14951 2440 274  16033 4590 231
Inj-6 14302 2201 220  16238 4621 223
Inj-7 14959 2313 255  16341 4546 236
Inj-8 15585 2494 270  16079 4489 236
Average 15108±399 2467±144 264±18  15509±681 4422±153 227±7
Biological sample
S-1 15112 3590 264  18128 5791 214
S-2 14753 3363 266  17164 5561 197
S-3 15184 3625 274  17875 5572 201
S-4 14699 3560 262  18193 5503 205
S-5 15075 3673 276  17922 5371 186
S-6 14776 3514 278  17082 5457 189
S-7 14844 3463 242  17806 5806 196
S-8 15514 3553 279  17450 5519 217
S-9 14888 3623 237  17010 5235 196
S-10 14546 3550 243  17541 5788 202
Average 14939±269 3551±85 262±15  17617±410 5560±180 200±9
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Table 3.
Quantification information of metabolites that were detected by more than one platform with significant 
changes in their abundance levels between groups
Compound p-value Fold-change
GC×GC-MS  2DLC-MS(−) 2DLC-MS(+) GC×GC-MS  2DLC-MS(−) 2DLC-MS(+)
Taurine 4.6E-04 1.7E-03 3.2E-02 5.6 1.8 1.7
Ornithine 4.1E-02 4.1E-02 3.2E-02 0.6 0.7 0.9
Phenylalanine 2.8E-02 5.7E-01 2.4E-02 0.6 0.6 0.7
Malic acid 5.0E-02 4.9E-02 - 1.6 1.3 -
Hypotaurine - 1.4E-03 1.6E-03 - 2.2 2.3
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Table 4.
Pathways affected by the treatment difference between groups
Significantly impacted pathways p-value Match status
Integrated platforms
Aminoacyl-tRNA biosynthesis 1.1E-03 8/69
Arginine and proline metabolism 2.1E-03 6/44
Valine, leucine and isoleucine biosynthesis 4.1E-03 3/11
Butanoate metabolism 4.3E-03 4/22
Alanine, aspartate and glutamate metabolism 5.9E-03 4/24
Biosynthesis of unsaturated fatty acids 9.1E-03 5/42
D-Glutamine and D-glutamate metabolism 9.3E-03 2/5
Taurine and hypotaurine metabolism 2.4E-02 2/8
GC×GC-MS
Biosynthesis of unsaturated fatty acids 2.3E-03 5/42
Aminoacyl-tRNA biosynthesis 4.2E-03 6/69
Butanoate metabolism 1.3E-02 3/22
Alanine, aspartate and glutamate metabolism 1.7E-02 3/24
Valine, leucine and isoleucine biosynthesis 2.5E-02 2/11
2DLC-MS (−)
Taurine and hypotaurine metabolism 1.2E-03 2/8
Valine, leucine and isoleucine biosynthesis 2.4E-03 2/11
Citrate cycle (TCA cycle) 8.0E-03 2/20
Butanoate metabolism 9.6E-03 2/22
Alanine, aspartate and glutamate metabolism 1.1E-02 2/24
D-Glutamine and D-glutamate metabolism 3.5E-02 1/5
Primary bile acid biosynthesis 3.9E-02 2/46
2DLC-MS (+)
Arginine and proline metabolism 2.3E-04 4/44
Taurine and hypotaurine metabolism 1.5E-03 2/8
Aminoacyl-tRNA biosynthesis 1.4E-02 3/69
Phenylalanine, tyrosine and tryptophan biosynthesis 3.1E-02 1/4
Cyanoamino acid metabolism 4.6E-02 1/6
Analyst. Author manuscript; available in PMC 2020 July 21.
